Dalpicilib combined with cetuximab

Phase 2Monoclonal antibody

SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Dalpicilib combined with cetuximab is one of 15 small molecule programs targeting HNSCC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HNSCCRecruiting

HNSCCPhase 2

Recruiting

Competition

Competitive Landscape

19 competitors in HNSCC

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 2

Opdivo

Bristol-Myers Squibb

Phase 1

2 3

Vectibix

Amgen

Phase 1

1 4

Methylthioninium Chloride

PProvepharm SAS

Phase 1

1 5

SG001

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2

1 6

Keytruda

Merck & Co.

Preclinical

2 7

Beyfortus

BeiGene

Preclinical

1 8

SYS6002

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 2

1 9

JMT101

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 2

1 10

Gilotrif

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Recruiting

HNSCC

NCT06935188

Clinical

Trials by Indication[1]

HNSCC1 trial

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06935188·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dalpicilib combined with cetuximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dalpicilib combined with cetuximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dalpicilib combined with cetuximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Dalpicilib combined with cetuximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

HNSCC1 trial

References

Drug Info

Quick Facts

Related News